Nasal anti-CD3 monoclonal antibody (Foralumab) for a patient with non-active SPMS

[agate]

This abstract of a paper presented by researchers at Harvard University involves only one patient but "additional patients are currently being treated." This statement in the abstract is worth noting, or at least it is for me since I seem to have this type of MS, and over the years I've been aware that there is still almost nothing available for it:

There are no effective treatments for non-active secondary progressive MS (SPMS), which is mediated by compartmentalized CNS inflammation, including activated microglia.

This is an abstract of a presentation at the recent CMSC (Consortium of Multiple Sclerosis Centers) conference (June 2, 2022)--"Nasal anti-CD3 monoclonal antibody (Foralumab) reduces PET microglial activation and blood inflammatory biomarkers in a patient with nonactive secondary progressive MS":

Only registered and activated users can see links., Click Here To Register...

IND = Investigational New Drug, and "expanded access IND" is explained on the FDA Website this way:

Expanded access, sometimes called "compassionate use," is the use of investigational new drug products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational drugs for patients who may benefit from investigational therapies.

[Virginia]

I am not quite sure what non-active means. I am SPMS, but I still have flair ups.

[agate]

If those are relapses, you're probably in the active SPMS category:

Only registered and activated users can see links., Click Here To Register...

I seem to have non-active SPMS with progression.

There's a MedPage Today article about this research but for the last two days I haven't been able to post it because the Website is undergoing maintenance.

[agate]

From MedPage Today (July 8, 2022) a brief article about this research by Lawrence Steinman, MD, of Stanford University--"Nasal Anti-CD3 Monoclonal Antibody Shows Promise in Progressive MS"--the video may not be working but the transcript of his remarks is there:

Only registered and activated users can see links., Click Here To Register...

[Lazarus]

Thanks…interesting